Democratic Oversight And Trump’s Rx Price Blueprint: Three Possible Routes

House Democrats and the Trump Administration share an interest in taking on high drug prices. They probably won’t cooperate – but will the House actively block administrative changes?

view of three wooden directional signs on a pole - Image

As the new Democratic majority in the House gets ready to conduct sweeping oversight of the Trump Administration, it faces an interesting decision on how to approach the Trump Administration’s “Blueprint” on drug pricing.

On the one hand, HHS under Secretary Alex Azar has shown a willingness to push administrative reforms aggressively, with a...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Pricing Debate

More from Market Access